Core Viewpoint - The article highlights the successful IPO of Hangzhou Deshi Biotechnology Co., Ltd. ("Deshi"), which has become the first stock in the field of medical imaging large models, raising approximately 800 million HKD through its public offering [2][3]. Group 1: IPO and Market Performance - Deshi officially listed on the Hong Kong Stock Exchange on March 30, 2026, under the stock code "2526" [2]. - The IPO saw a subscription rate of 1,073.37 times for the public offering and 3.45 times for the international offering, indicating strong investor interest [2]. - The stock opened at 219 HKD, a 121% increase from the issue price, with a market capitalization exceeding 20 billion HKD at one point [3]. Group 2: Business Model and Growth - Established in 2016, Deshi has developed a diversified business matrix that includes medical imaging software, medical devices, reagents, and technology licensing [3]. - The company has achieved significant commercial progress, with services covering over 400 medical institutions nationwide and a revenue growth of 469.82% year-on-year in the first three quarters of 2025 [4]. Group 3: Product Development and Market Position - Deshi's core product, AI AutoVision®, is designed for chromosome karyotype analysis and has completed clinical trials, with plans for regulatory approval in May 2025 [7]. - The company holds a 30.6% market share in the chromosome karyotype analysis field in China, positioning itself as a market leader [8]. - The Chinese market for chromosome analysis is projected to expand rapidly, reaching 2.038 billion RMB by 2030 and further increasing to 6 billion RMB by 2035 [8]. Group 4: Technological Innovation - Deshi's iMedImage® medical imaging base model supports 19 types of medical imaging modalities and covers over 90% of clinical imaging scenarios [10]. - The company plans to enhance the iMedImage® model's capabilities and expand its applications across various clinical settings, aiming to facilitate the intelligent transformation of the healthcare industry [11].

Core Viewpoint - The article provides an overview of recent IPO activities in the Hong Kong, US, and A-share markets, highlighting key companies such as Yushu Technology, Deshi Biotechnology, and SmartMore Inc. Group 1: Yushu Technology - Yushu Technology's IPO application was accepted on March 20, aiming to raise CNY 4.202 billion [3] - Founded in 2016, Yushu Technology focuses on self-research in general robotics, achieving significant market share in quadruped and humanoid robots, especially overseas [3] - The company sold over 30,000 quadruped robots from 2022 to 2024, establishing a strong position in the global market [3] - Yushu Technology's revenue is projected to reach CNY 1.708 billion in 2025, with a year-on-year growth of 335.36%, and a net profit of CNY 600 million, up 674.29% [4] - Major investors include Meituan, Sequoia China, and Matrix Partners, with Meituan holding 9.65% of shares [4] Group 2: Deshi Biotechnology - Deshi Biotechnology commenced its IPO process on March 19, with plans to list on the Hong Kong Stock Exchange under the code "2526" [6] - The company aims to raise up to HKD 900 million through the issuance of 7,999,200 shares, with a market valuation potentially reaching nearly HKD 10 billion [6] - Deshi Biotechnology specializes in medical imaging products, with its core product, AI AutoVision®, designed for chromosome karyotype analysis, already completing clinical trials [7] - The company holds a 30.6% market share in China's chromosome karyotype analysis sector, leading the market as of 2024 [8] Group 3: SmartMore Inc. - SmartMore Inc. submitted its IPO application to the Hong Kong Stock Exchange on March 16, aiming to become the first "Industrial AI Intelligent Agent" stock [10][11] - The company provides a comprehensive AI technology system for manufacturing, serving over 730 clients globally, including Tesla and BOE [11] - Revenue projections for SmartMore Inc. are CNY 485 million in 2023, CNY 756 million in 2024, and CNY 1.086 billion in 2025, with growth rates of 55.9% and 43.7% respectively [11] - The company has received investments from notable firms, achieving a valuation of USD 1.23 billion before its IPO [12][13]

Core Viewpoint - The article discusses the IPO of Hangzhou Deshi Biotechnology Co., Ltd., which aims to raise approximately HKD 900 million and achieve a market valuation of nearly HKD 10 billion, positioning itself as the first stock in the field of medical imaging large models [1]. Group 1: IPO Details - Deshi Biotechnology plans to issue 7,999,200 H-shares, with 799,950 shares for public offering in Hong Kong and 7,199,250 shares for international offering, at a price range of HKD 95.6 to HKD 112.5 per share [1]. - The IPO subscription period starts today and ends on the 25th, with the listing on the Hong Kong Stock Exchange scheduled for March 30, 2026, under the stock code "2526" [1]. Group 2: Product Overview - The core product, AI AutoVision®, is designed for chromosome karyotype auxiliary diagnosis, targeting areas such as birth defect prevention and assisted reproduction [2]. - AI AutoVision® has completed clinical trials, achieving a sensitivity of 100% and specificity of 100% in detecting abnormal numbers, and a sensitivity of 94.05% and specificity of 100% in detecting structural abnormalities [3]. Group 3: Market Position and Growth - According to Frost & Sullivan, Deshi Biotechnology holds a 30.6% market share in China's chromosome karyotype analysis sector, which is expected to grow rapidly to RMB 2.038 billion by 2030 and RMB 6 billion by 2035 [4]. - The company is positioned to capitalize on the anticipated market trends due to its leading role in chromosome analysis technology in mainland China [4]. Group 4: Technological Advantages - The success of AI AutoVision® is attributed to the iMedImage® medical imaging base model, which supports 19 types of medical imaging modalities and covers over 90% of clinical scenarios [5]. - Deshi Biotechnology plans to enhance the iMedImage® model's capabilities and expand its applications across various clinical settings [5]. Group 5: Regulatory Alignment - The development direction of Deshi Biotechnology aligns with national strategies, as the National Health Commission aims to promote AI-assisted clinical diagnosis services in hospitals by 2030 [6]. Group 6: Financial Performance - In the first three quarters of 2025, Deshi Biotechnology reported revenue of RMB 112 million, a 470% increase from RMB 20 million in the same period of 2024, with a gross margin of 75.9% [7]. - The global medical imaging market is projected to grow from USD 65 billion in 2019 to USD 95.7 billion in 2024, with China's market expected to reach RMB 159 billion by 2030 and RMB 219.3 billion by 2035 [7].

Core Viewpoint - The article highlights that Deshi Biotechnology is set to become the first publicly listed company focused on medical imaging AI models, aligning its development direction with national strategies for healthcare innovation [1][2]. Company Overview - Deshi Biotechnology, established in 2016, specializes in developing medical imaging products and services, with a diverse product portfolio that includes six medical imaging software products, three commercialized medical devices, four main reagents and consumables, and two licensed technology products [2]. Key Product Details - The core product, AI AutoVision®, is designed for chromosome karyotype analysis and is intended for use in birth defect prevention, pre-marital and pre-pregnancy screening, and assisted reproduction. It has completed clinical trials and is set to submit a Class III medical device registration application to the National Medical Products Administration in May 2025 [3]. - In a clinical trial involving 1,518 real samples, AI AutoVision® achieved a sensitivity of 100.00% and specificity of 100.00% for detecting numerical abnormalities, and a sensitivity of 94.05% and specificity of 100.00% for structural abnormalities, demonstrating significant efficiency improvements over traditional methods [3]. Market Position - According to Frost & Sullivan, Deshi Biotechnology holds the leading market share of 30.6% in China's chromosome karyotype analysis sector, with the market expected to grow rapidly to RMB 2.038 billion by 2030 and further to RMB 6.000 billion by 2035 [4]. Technological Advantages - The success of AI AutoVision® is attributed to the proprietary iMedImage® medical imaging base model, which supports 19 imaging modalities and covers over 90% of clinical imaging scenarios. This model is designed for reasoning-oriented learning and training in the medical field [5][6]. Future Development Plans - Deshi Biotechnology plans to enhance the iMedImage® model's capabilities to support a broader range of imaging modalities and clinical specialties, as well as improve its computational power for processing large-scale medical imaging data [7]. - The company aims to authorize the iMedImage® model for localized deployment to address challenges in remote areas, thereby supporting local healthcare institutions [7]. Financial Performance - For the first three quarters of 2025, Deshi Biotechnology reported revenue of RMB 112 million, a 470% increase from RMB 20 million in the same period of 2024, with a gross margin of 75.9% [8]. - The funds raised from the IPO will primarily be used for the R&D and commercialization of AI AutoVision®, as well as for developing other medical imaging software and devices, enhancing AI technology, and expanding market penetration both domestically and globally [8].

Core Viewpoint - The article discusses the recent progress of Hangzhou Deshi Biotechnology Co., Ltd. in its IPO application process in Hong Kong, positioning itself as a potential leader in the medical imaging AI sector, specifically aiming to become the first company in this field to go public [2]. Company Overview: Focused on Medical Imaging AI - Deshi Biotechnology, established in 2018 and headquartered in Hangzhou, specializes in medical imaging artificial intelligence and intelligent diagnostic software, with core technologies covering imaging algorithms and AI model training platforms [3]. - The company does not pursue a "general large model" approach but focuses on specific clinical scenarios such as hematology and cytogenetics, creating a relatively vertical AI product system tailored to real application needs in laboratories and clinics [3]. Products and Technology: Advancing to Full Automation - The main commercial products include AutoVision® and MetaSight®, which have been implemented in some medical institutions [4]. - The core product, AI AutoVision®, is designed as a fully automated, end-to-end cytogenetic analysis system, aiming to elevate the current semi-automated detection to a higher level of automation [8]. Financial Performance: Rapid Revenue Growth - Deshi Biotechnology has shown continuous revenue growth, with a significant acceleration in commercialization since 2025 [9]. - Revenue data reveals: - 2023: Revenue of 52.844 million RMB - 2024: Revenue of 70.352 million RMB, a year-on-year increase of 33.1% - For the nine months ending September 30, 2025: Revenue of 111.6 million RMB, a substantial increase of 469.8% compared to 19.588 million RMB in the same period of 2024 [12]. - Sales of AutoVision® and MetaSight® increased by 40.9% and 160.0% respectively, with an increase in average selling prices due to a higher direct sales ratio [13]. Profitability Situation - The company is still in the investment phase, with R&D expenditures and sales system development impacting short-term profitability [14]. - For the nine months ending September 30, 2025, the net loss was approximately 36.6 million RMB, a reduction from 50.8 million RMB in the same period of 2024 [19]. Observations: A Vertical AI Company - Deshi Biotechnology adopts a vertical approach focused on specific testing scenarios rather than the common narrative of general medical large models [15]. - The financial structure indicates that the company has moved beyond pure R&D and is entering a phase of commercialization and revenue growth, but the sustainability of its business model will depend on the approval and large-scale implementation of its core product, AI AutoVision® [15].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has disclosed that five companies have recently obtained approval for overseas issuance and listing or full circulation of unlisted shares in China, all targeting the Hong Kong Stock Exchange and are in the process of secondary applications [1] Group 1: Company Summaries - Stone Technology, once known as a "sweeping broom" in the A-share market, saw its stock price peak at 1494.99 yuan per share in June 2021, with a market capitalization of 99.266 billion yuan, but has since decreased to a total market value of 42.361 billion yuan, representing a decline of over 50%. The company plans to issue no more than 33.108 million shares [1] - Haizhi Technology, an AI application company founded by former Baidu executives and backed by Hillhouse Capital, focuses on products like the Atlas mapping solution and Atlas intelligent agents. It intends to issue no more than 47.5846 million shares and convert 372 million shares held by shareholders into H-shares [1] - Yushi Technology specializes in L4-level autonomous driving technology, with investors including Innovation Works. The company plans to issue no more than 18.9142 million shares and convert 112 million shares held by shareholders into H-shares [1] - Deshi Biotech aims to become the first company to launch a medical imaging large model, planning to issue no more than 31.004 million shares and convert 80.88 million shares held by shareholders into H-shares [1] - Shangmi Technology, a provider of commercial IoT (BIoT) solutions with shareholders including Ant Group, Meituan, and Xiaomi, plans to issue no more than 46.004 million shares and convert 261 million shares held by shareholders into H-shares [1]

Core Viewpoint - Hangzhou Deshi Biotechnology Co., Ltd. is advancing its IPO process on the Hong Kong Stock Exchange, aiming to become the first company in the field of medical imaging large models, with significant revenue growth driven by its unique market position and favorable policies [1][2]. Group 1: Company Overview - Established in 2016, Deshi Biotechnology focuses on AI in medical imaging and smart equipment, offering a diverse product portfolio including six software products, three commercial medical devices, four main reagents and consumables, and two technology licensing products [2]. - The core product, AI AutoVision®, specializes in intelligent analysis of chromosome karyotypes, having completed clinical trials and received recognition as a Class III innovative medical device from the National Medical Products Administration [2]. Group 2: Technology and Innovation - The success of AI AutoVision® is supported by the underlying technology platform iMedImage™, which enhances product functionality and cross-scenario applications, covering 19 types of medical imaging modalities and over 90% of clinical scenarios [3]. - iMedImage™ is noted as the largest medical imaging base model globally, integrating pre-trained medical imaging technology, thus overcoming limitations of disease-specific and modality-specific small models [3]. Group 3: Market Potential - The AI medical imaging market in China is projected to grow from 2.4 billion yuan in 2024 to 40.1 billion yuan by 2030, with a compound annual growth rate of 60.2% [4]. - Policy support is evident, with the National Health Commission and other departments promoting AI medical imaging applications, aiming for widespread clinical diagnostic services in hospitals by 2030 [4]. Group 4: Funding and Future Plans - Deshi Biotechnology has secured investments from various institutions and plans to use IPO proceeds primarily for the development and commercialization of AI AutoVision®, as well as for other software and medical device R&D [4].